Get a fresh start.
Add this topic to your myFT Digest for news straight to your inbox
Sales rose 12 per cent driven by a rise in revenue from tumour treatment Keytruda
Dovato shown to be as effective as Gilead’s traditional combination treatment
Amgen, Merck and Eli Lilly say Trump administration’s move infringes on free speech
Hopeful results for blockbuster immunotherapy drug
Group that is developing a renal cancer treatment had been planning a New York listing
Pfizer, Eli Lilly and Merck raise earnings forecasts for 2019
US pharmaceutical company reported better than expected sales and earnings
Merck collaboration for new generation of pills could be worth as much as $340m
Rapid medical innovation is prompting drug company mergers and making treatment costly
Virgin looks to expand in the US, Theresa May is expected to ask MPs for more time t…
The immunotherapy used with Pfizer’s Inlyta halves the risk of dying from condition
The biggest movers include Goldman Sachs, Merck and AMD
The pharma company reported a third-quarter profit compared to last year’s loss
Patients taking US group’s lung cancer drug lived longer than those on chemotherapy
Discordant notes expected at this year’s Asco, a kind of rock festival for pharma
Company says test results show ‘unambiguous’ improvement in survival rates
Merck slides and Incyte loses $4bn market value as ‘combination’ cancer study flops
Clinical setbacks in cancer research are likely to be punished
Japanese group’s tie-up with US pharma on cancer drug will boost its research on Alzheimer’s
Companies analysis from our sister publication
